, CHRONIC LYMPHOID LEUKEMIA SECONDARILY ASSOCIATED WITH A MALIGNANT RETICULOPATHY
, Hématologie, vol.4, pp.621-644, 1964.
A systematic review on Richter syndrome: what is the published evidence?, Leuk. Lymphoma, vol.51, pp.415-421, 2010. ,
Richter syndrome: molecular insights and clinical perspectives, Hematol. Oncol, vol.27, pp.1-10, 2009. ,
CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?, Blood, vol.111, pp.5646-5653, 2008. ,
Clinical outcomes and prognostic factors in patients with Richter"s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, pp.2343-2351, 2006. ,
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation, Blood, vol.117, pp.3391-3401, 2011. ,
Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter"s syndrome, Leukemia, vol.18, pp.326-330, 2004. ,
Molecular pathogenesis of transformed lymphomas, Hematol. Oncol, vol.33, issue.1, pp.70-74, 2015. ,
The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas, Pathol. Oncol. Res. POR, vol.22, pp.567-577, 2016. ,
Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients" survival benefit from rituximab, Eur. J. Haematol, vol.81, pp.448-453, 2008. ,
PD-L1 expression on tolerogenic APCs is controlled by STAT-3, Eur. J. Immunol, vol.41, pp.413-424, 2011. ,
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5032, 2011. ,
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, vol.103, pp.275-282, 2004. ,
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, N. Engl. J. Med, vol.346, pp.1937-1947, 2002. ,
Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP, Int. J. Clin. Exp. Pathol, vol.8, pp.275-286, 2015. ,
PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications, Oncotarget, 2016. ,
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT983936, Leukemia, vol.17, pp.2257-2317, 2003. ,
Richter"s transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group, Am. J. Hematol, vol.89, pp.218-222, 2014. ,
, A predictive model for aggressive non-Hodgkin"s lymphoma. The International NonHodgkin"s Lymphoma Prognostic Factors Project, N. Engl. J. Med, vol.329, pp.987-994, 1993.
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011), Leuk. Lymphoma, vol.54, pp.252-254, 2013. ,
Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior, Haematologica, vol.95, pp.1526-1533, 2010. ,
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes, Leuk. Lymphoma, vol.56, pp.1643-1650, 2015. ,
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N. Engl. J. Med, vol.369, pp.134-144, 2013. ,
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med, vol.366, pp.2443-2454, 2012. ,
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin"s lymphoma, N. Engl. J. Med, vol.372, pp.311-319, 2015. ,
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma, Blood, vol.126, pp.2193-2201, 2015. ,
Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas, Hum. Pathol, vol.54, pp.17-24, 2016. ,
PD-L1 Expression is Characteristic of a Subset of Aggressive B-Cell Lymphomas and Virus-Associated Malignancies, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.19, pp.3462-3473, 2013. ,
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial, Leukemia, vol.28, pp.2367-2375, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-00981338
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies, Biochim. Biophys. Acta, vol.1865, pp.58-71, 2016. ,
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi, Br. J. Haematol, vol.169, pp.544-551, 2015. ,
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions, Nature, vol.401, pp.708-712, 1999. ,
Memory, and Dysfunctional CD8+ T Cell Fates in the Antitumor Immune Response, J. Immunol. Res, 2016. ,
DOI : 10.1155/2016/8941260
URL : http://downloads.hindawi.com/journals/jir/2016/8941260.pdf
Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group, Histopathology, vol.60, pp.313-319, 2012. ,
High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma, Hematol. Oncol, vol.33, pp.110-112, 2015. ,
New vistas on macrophage differentiation and activation, Eur. J. Immunol, vol.37, pp.14-16, 2007. ,
DOI : 10.1002/eji.200636910
URL : http://onlinelibrary.wiley.com/doi/10.1002/eji.200636910/pdf
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.403, pp.503-511, 2000. ,
DOI : 10.1038/35000501
High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy, Haematologica, vol.96, pp.996-1001, 2011. ,
DOI : 10.3324/haematol.2010.037408
URL : http://www.haematologica.org/content/haematol/96/7/996.full.pdf
Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy, Am. J. Clin. Pathol, vol.145, pp.514-523, 2016. ,
The revised European-American lymphoma (REAL) classification, Clin Oncol (R Coll Radiol), vol.7, issue.6, pp.347-355, 1995. ,
DOI : 10.1016/s0936-6555(05)80003-2
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5051, 2011. ,
DOI : 10.1182/blood-2011-01-293050
URL : http://www.bloodjournal.org/content/117/19/5019.full.pdf
Cancer incidence in France over the 1980-2012 period: Hematological malignancies, Rev Epidemiol Sante Publique, vol.64, issue.2, pp.103-115, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01511580
Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor, Blood, vol.89, issue.7, pp.2291-2298, 1997. ,
Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas, Br J Haematol, vol.109, issue.3, pp.584-91, 2000. ,
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles, Lancet, vol.381, issue.9880, pp.1817-1843, 2013. ,
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d"Etudes des Lymphomes de l, Adulte. Blood, vol.116, issue.12, pp.2040-2045, 2010. ,
State-of-the-art therapeutics: diffuse large B-cell lymphoma, J Clin Oncol, vol.23, issue.26, pp.6387-93, 2005. ,
Report of the Committee on Hodgkin"s Disease Staging Classification, Cancer Res, vol.31, issue.11, pp.1860-1861, 1971. ,
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, vol.109, pp.1857-61, 2007. ,
Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification, Br J Cancer, vol.79, pp.1770-1776, 1999. ,
Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study, Br J Haematol, vol.112, issue.4, pp.945-954, 2001. ,
MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified, PLoS ONE, vol.9, issue.8, p.104068, 2014. ,
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study, Blood, vol.126, issue.22, pp.2466-74, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01543654
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.403, issue.6769, pp.503-514, 2000. ,
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, N Engl J Med, vol.346, issue.25, pp.1937-1984, 2002. ,
Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes, Genes Chromosomes Cancer, vol.51, issue.9, pp.858-67, 2012. ,
Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study, Blood, vol.116, issue.7, pp.1092-104, 2010. ,
URL : https://hal.archives-ouvertes.fr/ensl-00816038
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, vol.103, issue.1, pp.275-82, 2004. ,
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy, Clin Cancer Res, vol.15, issue.17, pp.5494-502, 2009. ,
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab, J Clin Oncol, vol.29, issue.2, pp.200-207, 2011. ,
Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy, Leuk Lymphoma, pp.1-7, 2016. ,
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, J Clin Oncol, vol.30, issue.28, pp.3452-3461, 2012. ,
Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma, Onco Targets Ther, vol.8, pp.2645-50, 2015. ,
Recent advances in de novo CD5+ diffuse large B cell lymphoma, Am J Hematol, vol.88, issue.9, pp.798-802, 2013. ,
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP, Mod Pathol, vol.28, issue.12, pp.1555-73, 2015. ,
Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large Bcell lymphoma treated with R-CHOP, Int J Clin Exp Pathol, vol.8, issue.1, pp.275-86, 2015. ,
A populationbased study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients, Acta Oncol, pp.1-6, 2016. ,
De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression, Diagn Pathol, vol.8, p.81, 2013. ,
Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma, Blood, vol.117, issue.18, pp.4726-4761, 2011. ,
The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas, Pathol Oncol Res, vol.22, issue.3, pp.567-77, 2016. ,
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies, Biochim Biophys Acta, issue.1, pp.58-71, 1865. ,
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma, Blood, vol.126, pp.2193-201, 2015. ,
MicroRNAs as novel biomarkers in diffuse large B-cell lymphoma-a systematic review, Dan Med J, vol.62, issue.5, 2015. ,
, SEER Cancer Statistics Review 1975-2001-Previous Version-SEER Cancer Statistics
Chronic lymphocytic leukemia in young individuals revisited, Haematologica, vol.99, issue.1, pp.4-5, 2014. ,
Link found between Agent Orange and chronic lymphocytic leukaemia, BMJ, vol.326, issue.7383, p.242, 2003. ,
From pathogenesis to treatment of chronic lymphocytic leukaemia, Nat Rev Cancer, vol.10, issue.1, pp.37-50, 2010. ,
Familial Chronic Lymphocytic Leukemia, Curr Opin Hematol, vol.17, issue.4, pp.350-355, 2010. ,
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, Blood, vol.111, issue.12, pp.5446-56, 2008. ,
The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL, Leukemia, vol.8, issue.10, pp.1640-1645, 1994. ,
B-zone small lymphocytic lymphoma: a morphologic, immunophenotypic, and clinical study with comparison to "well-differentiated" lymphocytic disorders, Hum Pathol, vol.23, issue.4, pp.438-486, 1992. ,
The lymph node in chronic lymphocytic leukemia, Cancer, vol.41, issue.1, pp.283-92, 1978. ,
Bchronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström"s macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders, Semin Hematol, vol.36, issue.2, pp.104-118, 1999. ,
Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study, Histopathology, vol.24, issue.5, pp.445-51, 1994. ,
Clinical staging of chronic lymphocytic leukemia, Blood, vol.46, issue.2, pp.219-253, 1975. ,
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis, Cancer, vol.48, issue.1, pp.198-206, 1981. ,
Genetics of small lymphocyte disorders, Semin Hematol, vol.36, issue.2, pp.171-178, 1999. ,
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia, N Engl J Med, vol.353, issue.17, pp.1793-801, 2005. ,
Trisomy 12 in chronic lymphocytic leukemia. An interphase cytogenetic study by fluorescence in situ hybridization, Cancer Genet Cytogenet, vol.72, issue.2, pp.83-88, 1994. ,
Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?, J Clin Oncol, vol.32, issue.9, pp.869-72, 2014. ,
11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis, Blood, vol.89, issue.7, pp.2516-2538, 1997. ,
Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors, Blood, vol.100, issue.4, pp.1177-84, 2002. ,
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile, Blood, vol.15, issue.12, pp.4944-51, 2003. ,
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia, Leukemia, vol.16, issue.1, pp.30-35, 2002. ,
A systematic review on Richter syndrome: what is the published evidence? Leuk Lymphoma, vol.51, pp.415-436, 2010. ,
, Nouv Rev Fr Hematol, vol.4, pp.621-665, 1964.
Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience, Cancer, vol.107, issue.6, pp.1294-302, 2006. ,
New Developments in Richter Syndrome, 2016. ,
Richter syndrome: molecular insights and clinical perspectives, Hematol Oncol, vol.27, issue.1, pp.1-10, 2009. ,
CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood, vol.111, pp.5646-53, 2008. ,
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011), Leuk Lymphoma, vol.54, issue.2, pp.252-256, 2013. ,
s transformation in chronic lymphocytic leukemia, Oncology, vol.26, issue.12, pp.1146-52, 2012. ,
Clinical outcomes and prognostic factors in patients with Richter"s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation, J Clin Oncol, vol.24, issue.15, pp.2343-51, 2006. ,
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation, Blood, vol.117, issue.12, pp.3391-401, 2011. ,
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936, Leukemia, vol.17, issue.12, pp.2257-317, 2003. ,